Introduction
are viable. In adults, it is not known yet whether the three HASisoforms serve specific functions in the cardiovascular system and/or the pathophysiology of cardiovascular disease. We have recently observed that prostacyclin (PGI2) and prostaglandin E2 (PGE2) markedly induce HAS2 and HAS1 expression in cultured human VSMC [9, 10] . Cyclooxygenase 1 (COX-1) and COX-2 are constitutively expressed in endothelial cells, whereas COX-2 is strongly induced in VSMC by many of the major pro-atherogenic mediators such as PDGF-BB, cytokines, thrombin and oxidized LDL [11] . Therefore, we hypothesize that prostaglandins could indeed be key regulators of sustained neointimal HA-synthesis.
Because non-steroidal anti-inflammatory drugs (NSAID) that inhibit COX-dependent prostaglandin synthesis are widely used, this regulatory pathway might be of clinical relevance. Furthermore, in the light of the ongoing discussion about adverse cardiovascular effects of COX-2 inhibition, it will be important to consider also chronic effects on plaque remodelling [12] . Therefore, the role of COX products specifically in vascular HA synthesis was assessed in murine models of accelerated atherosclerosis and neointimal hyperplasia using the two prototypic non-isoform selective and COX-2-selective inhibitors, indomethacin and rofecoxib. [14] . 
Materials and methods

Animals and experimental design
Characterization of mRNA expression
The expression levels were analyzed by quantitative real-time RT-PCR. Aliquots of total RNA (1000 ng) were applied for cDNA-synthesis using Superscript-III First-Strand synthesis system for RT-PCR (Invitrogen, Karlsruhe, Germany). Real-time RT-PCR analysis of mouse HAS1-3 and GAPDH was performed as described previously
Immunohistochemical analysis
Histochemical stainings
Three-micrometre paraffin sections of the aortic root were stained for collagen accumulation by picrosirius red. Qualitative analysis of collagen deposition was performed using polarized light microscopy.
Statistical analysis
Data are presented as the mean Ϯ S.E.M. Statistical analysis was performed by unpaired t-test or one-way ANOVA followed by comparison of selected pairs (Bonferroni). A value of P Ͻ0.05 was considered significant.
Resuπlts
HA-accumulation in atherosclerotic plaques
Mass spectrometric quantitation of urinary thromboxane A2 (TxA2) metabolite (2, , an index of platelet COX-1 activity, revealed complete depression by indomethacin (P Ͻ 0.05) and no effect of rofecoxib (Fig. 1C) . PGI2 biosynthesis as assessed by quantitation of its urinary metabolite, 2,3-dinor-6-keto-PGF1␣, was depressed by Ͼ90% by indomethacin (P Ͻ 0.05) and by 75% by rofecoxib (P Ͻ 0.05). Roughly, 70% of PGI2 formation is COX-2 dependent in mice [15] . Thus, rofecoxib acted, indeed, as selective inhibitor of COX-2 at our dosing regimen, whereas indomethacin inhibited -as expected -both isoenzymes (Fig. 1C) Fig. 2A-D (Fig. 3) , as would be expected with COX-1 inhibition [16] .
To (Fig. 4) 
HA-accumulation after ligation injury
Rapid induction of neointimal hyperplasia occurs in ApoE-deficient mice after ligation of the carotid artery [13] 
. In this model, neointimal hyperplasia is driven mainly by SMC proliferation and migration and was used in comparison with the chronic model of atherogenesis as detailed earlier. Neointimal hyperplasia was significantly reduced by indomethacin that corresponded to decreased frequency of thrombotic occlusion of ligated carotid arteries (not shown). Arteries with thrombus formation were excluded from further analysis. In contrast, rofecoxib had no effect on neointima formation (not shown).
HA-accumulation was detected in the luminal part of the neointima and found to be strongly reduced by treatment with rofecoxib and indomethacin (Fig. 5A-D) . Furthermore, only HAS1 mRNA expression was dramatically reduced by both COX inhibitors (Fig. 5E) , whereas HAS2 was not changed. Moreover, indomethacin resulted in increased staining of alpha SM-actin in neointimal hyperplasia (Fig. 5F-I ) similar to the effects observed in atherosclerotic
Fig. 1 Experimental design. (A) ApoE-deficient mice were treated with indomethacin (3 mg/kg/day) or rofecoxib (50 mg/kg/day) for 8 weeks beginning at 15 weeks of age on normal chow. (B) Neointimal hyperplasia in the left carotid artery was induced by permanent ligation at the age of 10 weeks in ApoE-deficient mice. Starting with the ligation animals were fed Western diet and treated with indomethacin or rofecoxib as described in (A). (C) Urinary excretion of the prostacyclin (PGI2) metabolite (2,3-dinor-6-keto PGF1␣) and the thromboxane (Tx) A2 metabolite (2,3-dinor TxB2) was measured by tandem mass spectroscopy to monitor COX-2 and platelet COX-1 activity, respectively.
Fig. 2 Aortic root lesions of ApoE-deficient mice stained for HA (A-D). (A) Control; (B) indomethacin (8 weeks, 3 mg/kg/day); (C) rofecoxib (8 weeks, 50 mg/kg/day); (D) densitometric quantitation of HA affinity histochemistry; (E) aortic mRNA expression of HAS isoforms; n ϭ 15-12, mean Ϯ S.E.M., *P Ͻ 0.05.
Fig. 3 VSMC (␣-SM actin, A-D) and macrophage (mac2, E-H) content of aortic root lesions of ApoE-deficient mice after treatment with COX inhibitors.
A, E, controls; B, F indomethacin (8 weeks, 3 mg/kg/day); C, G, rofecoxib (8 weeks, 50 mg/kg/day); densitometric quantitation of D, ␣-SM actin and H, mac2
; n ϭ 12, mean Ϯ S.E.M., *P Ͻ 0.05.
Fig. 4 Collagen content of aortic root lesions of ApoE-deficient mice indicated by picrosirius red staining after treatment with COX inhibitors. Total collagen was evaluated by light microscopy (A-D) and collagen arrangement was analyzed by birefringence analysis using polarized light (E-H). A, E, controls; B, F indomethacin (8 weeks, 3 mg/kg/day); C, G, rofecoxib (8 weeks, 50 mg/kg/day); densitometric quantitation of D, picrosirius red staining, light microscopy and H, picrosirius red staining under polarized light to visualize densely packed collagen (bright red)
Fig. 5 HA-accumulation in neointimal hyperplasia 4 weeks after ligation of the left carotid artery of ApoE-deficient mice on a Western diet. (A) Control; (B) indomethacin (4 weeks, 3 mg/kg/day); (C) rofecoxib (4 weeks, 50 mg/kg/day); (D) densitometric quantitation of HA-affinity histochemistry in the neointima; (E) mRNA expression of HAS isoforms in ligated carotid arteries; (F-H) ␣-SM-actin staining; densitometric quantification of ␣-SM-actin;
n ϭ 4-7; mean Ϯ S.E.M., *P Ͻ 0.05. [17] , COX-2 deletion or inhibition may accelerate [18] , retard [19] or leave lesion progression unaltered [20] 
lesions (compare to Fig. 3). Macrophage accumulation as evidenced by immunohistochemistry of mac2 was not responsive to COX inhibition in the carotid injury model (Fig. 6). Similar to the results in atherosclerotic plaques, the amount collagen deposited in the neointima was not affected (not shown).
Discussion
The biology of the COXs in vascular lesions is not well understood. Multiple cell types such as macrophages, VSMC and endothelial cells expressing COX-1, COX-2 or both interact during the devel
